COVID-19 Oral Drug: Hetero Announces Interim Clinical Trial Results of Antiviral Drug Molnupiravir in Mild Coronavirus Patients
In April this year, Hetero had entered into a non-exclusive licensing agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., the US, to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).